LEHI, Utah, Oct. 7, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting inflammasome-driven disease biology, today announced that the Company plans to participate in the 6th Annual Needham Private Biotech & MedTech Company Virtual 1x1 Forum, taking place October 13-14, 2026.
About Halia Therapeutics
Halia Therapeutics is a clinical-stage biotechnology company headquartered in Lehi, Utah, developing first-in-class therapies that target inflammasome-driven disease biology. The company focuses on addressing significant unmet needs in hematologic diseases through novel mechanisms designed to target the root causes of inflammation-driven pathology. Halia's lead program, ofirnoflast, is being developed for lower-risk MDS and other hematologic diseases driven by NLRP3 inflammasome biology. Its broader pipeline is grounded in human genetic resilience and precision medicine. For more information, visit www.haliatx.com.
Investor Contact
Leigh Salvo
New Street Investor Relations
leigh@newstreetir.com
Media Contact
Taylor Avei, Head of Business Development
Halia Therapeutics
tavei@haliatx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halia-therapeuticsto-participate-in-the-6th-annual-needham-private-biotech--medtech-company-virtual-1x1-forum-302900689.html
SOURCE Halia Therapeutics
